A Multicenter, Open-Label, 2-Stage, Phase 1, Clinical Safety, Pharmacokinetic, And Pharmacodynamic Study Of CVX-045, A Thrombospondin-1 Mimetic, Anti-Angiogenic Agent, In Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2010
At a glance
- Drugs PF 4856882 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 10 Dec 2010 Actual end date changed from Dec 2010 to Nov 2010 as reported by ClinicalTrials.gov.
- 10 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jul 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.